Top

Published in:

Open Access 01-12-2017 | Review

A Review of the Use of Secukinumab for Psoriatic Arthritis

Authors: Nupur U. Patel, Nora C. Vera, Emily Rose Shealy, Margaret Wetzel, Steven R. Feldman

Published in: Rheumatology and Therapy | Issue 2/2017

Abstract

Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA. While indirect comparisons of indicate that secukinumab is as effective as other treatment options, further studies directly comparing available treatments will be necessary to establish its place in treatment guidelines. As these and other trials are conducted, the evidence produced will further elucidate the clinical potential of secukinumab as a treatment option for patients with rheumatologic disease.

National Psoriasis Foundation. Fact Sheet Library | National Psoriasis Foundation. https://www.psoriasis.org/publications/patient-education/fact-sheets. Accessed 30 May 2017.

Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–64. doi:10.1016/j.jaad.2008.02.040.CrossRefPubMed

Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71(4):649–55. doi:10.1016/j.jaad.2014.05.010.CrossRefPubMed

Cosentyx (secukinumab) [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2016.

Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3(1):5–29. doi:10.1007/s40744-016-0031-5.CrossRefPubMedPubMedCentral

Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–6. doi:10.1136/annrheumdis-2013-205056.CrossRefPubMed

Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98. doi:10.1056/NEJMra0707449.CrossRefPubMed

Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11(10):763–76. doi:10.1038/nrd3794.CrossRefPubMed

Smith JA, Colbert RA. Review: the interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: th17 and beyond. Arthritis Rheumatol. 2014;66(2):231–41. doi:10.1002/art.38291.CrossRefPubMedPubMedCentral

10.

Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–29. doi:10.1007/s11010-011-1036-6.CrossRefPubMed

11.

Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272–81. doi:10.1002/art.38376.CrossRefPubMedPubMedCentral

12.

Lubberts E, Joosten LA, Oppers B, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001;167(2):1004–1013. http://www.ncbi.nlm.nih.gov/pubmed/11441109. Accessed 6 Apr 2017.

13.

Novartis. Cosentyx summary of product characteristics. http://ec.europa.eu/health/documents/community-register/2015/20150115130444/anx_130444_en.pdf. Accessed 30 July 2017.

14.

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39. doi:10.1056/NEJMoa1412679.CrossRefPubMed

15.

McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349–56. doi:10.1136/annrheumdis-2012-202646.CrossRefPubMed

16.

McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46. doi:10.1016/S0140-6736(15)61134-5.CrossRefPubMed

17.

Kirkham B, McInnes I, Mease P, et al. THU0421 secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (future 2). Ann Rheum Dis. 2015;74:351. doi:10.1136/annrheumdis-2015-eular.2276.CrossRef

18.

Novartis. Expert insights on the approved uses of COSENTYX (secukinumab). In: American College of Rheumatology annual 2016 meeting. Washington, DC. 2016.

19.

Data on file. AIN457F summary of clinical safety in psoriatic arthritis. Novartis Pharmaceuticals Corp. 2015.

20.

Gaffen SL, Hernández-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011;50(2–3):181–7. doi:10.1007/s12026-011-8226-x.CrossRefPubMedPubMedCentral

21.

Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–700. doi:10.1136/gutjnl-2011-301668.CrossRefPubMed

22.

Data on file. AIN457H summary of clinical efficacy in ankylosing spondylitis. Novartis Pharmaceuticals Corp. 2015.

23.

van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4. doi:10.1016/j.jaad.2016.03.024.CrossRefPubMed

24.

Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21–5. doi:10.1016/j.ijwd.2016.12.003.CrossRefPubMedPubMedCentral

25.

Koenders MI, van den Berg WB. Secukinumab for rheumatology: development and its potential place in therapy. Drug Des Dev Ther. 2016;10:2069–80. doi:10.2147/DDDT.S105263.CrossRef

26.

Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;. doi:10.1002/art.39573.CrossRefPubMed

27.

Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510. doi:10.1136/annrheumdis-2015-208337.CrossRefPubMed

28.

Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12(12):743–50. doi:10.1038/nrrheum.2016.183.CrossRefPubMed

29.

Coates LC, Murphy R, Helliwell PS. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016;174(6):1174–8. doi:10.1111/bjd.14667.CrossRefPubMed

30.

Oussedik E, Cardwell LA, Patel NU, Onikoyi O, Feldman SR. An anchoring-based intervention to increase patient willingness to use injectable medication in psoriasis. JAMA Dermatol. 2017. doi:10.1001/jamadermatol.2017.1271.

31.

Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066.CrossRefPubMed

Title: A Review of the Use of Secukinumab for Psoriatic Arthritis
Authors: Nupur U. Patel
Nora C. Vera
Emily Rose Shealy
Margaret Wetzel
Steven R. Feldman
Publication date: 01-12-2017
Publisher: Springer Healthcare
Published in: Rheumatology and Therapy / Issue 2/2017
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI: https://doi.org/10.1007/s40744-017-0076-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis

Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials